ReviewNeurogastroenterology and motility2020
Critical evaluation of animal models of visceral pain for therapeutics development: A focus on irritable bowel syndrome.
Review in Neurogastroenterology and motility, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- Changes in fecal short-chain fatty acids following fecal microbiota transplantation in patients with irritable bowel syndrome.Neurogastroenterology and motility · 2021Trial
- DSS Colitis Model: Traps, Tricks, and Reporting Recommendations.Biomedicines · 2026Review
- Better together? Individual and synergistic effects of noneuphorigenic cannabinoids on visceral sensation.The Journal of pharmacology and experimental therapeutics · 2025Article
- Article
- A Synbiotic Combining Chitin-Glucan andInternational journal of molecular sciences · 2024Article
- Targeting nerve growth factor for pain relief: pros and cons.The Korean journal of pain · 2024Review
- Effects of Stress Exposure to Pain Perception in Pre-Clinical Studies: Focus on the Nociceptin/Orphanin FQ-NOP Receptor System.Brain sciences · 2024Review
- Photobiomodulation improves acute restraint stress-induced visceral hyperalgesia in rats.Lasers in medical science · 2024Article
- Chitin-glucan improves important pathophysiological features of irritable bowel syndrome.World journal of gastroenterology · 2024Article
- Enteric glia promote visceral hypersensitivity during inflammation through intercellular signaling with gut nociceptors.Science signaling · 2023Article
- The Gut Microbial Bile Acid Modulation and Its Relevance to Digestive Health and Diseases.Gastroenterology · 2023Review
- Regional brain activation during rectal distention and attenuation with alosetron in a nonhuman primate model of irritable bowel syndrome.FASEB bioAdvances · 2022Article
- Long-lasting visceral hypersensitivity in a model of DSS-induced colitis in rats.Neurogastroenterology and motility · 2022Article
- Spinal Microglia and Astrocytes: Two Key Players in Chronic Visceral Pain Pathogenesis.Neurochemical research · 2022Review
- Guanylate cyclase-C agonists as peripherally acting treatments of chronic visceral pain.Trends in pharmacological sciences · 2022Review
- Depression and Pain: Use of Antidepressants.Current neuropharmacology · 2022Review
- Article
- Chronic Abdominal Pain in IBD Research Initiative: Unraveling Biological Mechanisms and Patient Heterogeneity to Personalize Treatment and Improve Clinical Outcomes.Crohn's & colitis 360 · 2021Article
- Review
- Animal models of visceral pain and the role of the microbiome.Neurobiology of pain (Cambridge, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
The classification of chronic visceral pain is complex, resulting from persistent inflammation, vascular (ischemic) mechanisms, cancer, obstruction or distension, traction or compression, and combined mechanisms, as well as unexplained functional mechanisms. Despite the prevalence, treatment options for chronic visceral pain are limited. Given this unmet clinical need, the development of novel analgesic agents, with defined targets derived from preclinical studies, is urgently needed. While various animal models have played an important role in our understanding of visceral pain, our knowledge is far from complete. Due to the complexity of visceral pain, this document will focus on chronic abdominal pain, which is the major complaint in patients with disorders of the gut-brain interaction, also referred to as functional gastrointestinal disorders, such as irritable bowel syndrome (IBS). Models for IBS are faced with challenges including a complex clinical phenotype, which is comorbid with other conditions including anxiety, depression, painful bladder syndrome, and chronic pelvic pain. Based upon the multifactorial nature of IBS with complicated interactions between biological, psychological, and sociological variables, no single experimental model recapitulates all the symptoms of IBS. This position paper will contextualize chronic visceral pain using the example of IBS and focus on its pathophysiology while providing a critical review of current animal models that are most relevant, robust, and reliable in which to screen promising therapeutics to alleviate visceral pain and delineate the gaps and challenges with these models. We will also highlight, prioritize, and come to a consensus on the models with the highest face/construct validity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.